Fenbendazole and Colorectal Cancer: What Laboratory Evidence Reveals

Fenbendazole is a benzimidazole anthelmintic compound that has attracted growing attention in oncology research for its potential effects against cancer cells. Originally developed as a veterinary deworming agent, its molecular profile — particularly its interaction with tubulin — has prompted researchers to investigate whether it may disrupt the growth of colorectal cancer (CRC) cell lines under controlled laboratory conditions.

Colorectal cancer is among the leading causes of cancer-related mortality worldwide, and resistance to standard chemotherapy remains a persistent clinical challenge. Laboratory studies have begun to characterize how fenbendazole may interfere with several biological pathways relevant to CRC, including microtubule dynamics, the p53 tumor suppressor pathway, and cellular glucose metabolism.

Mechanism of Action: Tubulin Disruption

Fenbendazole acts as a moderate microtubule-destabilizing agent by binding to β-tubulin and inhibiting its polymerization into functional microtubules. This mechanism is shared — though at different potency levels — with established chemotherapy agents such as taxanes and vinca alkaloids. A 2018 study by Dogra et al. published in Scientific Reports demonstrated that fenbendazole binds mammalian tubulin and produces cytotoxic effects in human cancer cells at micromolar concentrations, without significant toxicity to normal cells at those concentrations.

Disruption of microtubule polymerization has downstream consequences for cell division: cancer cells arrested at the G2/M phase of the cell cycle are unable to complete mitosis, eventually triggering apoptotic pathways. This selectivity for rapidly dividing cells — a hallmark of cancer — provides a mechanistic rationale for the observed differential toxicity between malignant and normal cell populations.

Effects on Colorectal Cancer Cell Lines

Multiple studies have examined fenbendazole’s activity in colorectal cancer models. In benzimidazole screening research published in Pharmaceuticals (Florio et al., 2021), fenbendazole demonstrated antiproliferative activity in colorectal cancer cell lines with IC50 values in the low micromolar to nanomolar range — comparable to several agents in clinical use.

A particularly notable 2022 study by Park et al. in the Korean Journal of Physiology and Pharmacology examined fenbendazole’s effects on the SNU-C5 colorectal cancer cell line, including a subline rendered resistant to 5-fluorouracil (5-FU), a cornerstone of CRC chemotherapy. The study found that fenbendazole retained its cytotoxic activity even in drug-resistant cells, inducing apoptosis and G2/M cell cycle arrest. In 5-FU-resistant cells, where p53 expression was reduced, ferroptosis — an iron-dependent form of programmed cell death — appeared as an additional death mechanism.

A 2020 review by Son, Lee, and Adunyah in Immune Network confirmed that benzimidazoles including fenbendazole exert anticancer effects in colorectal cancer models via microtubule polymerization disruption, G2/M arrest, anti-angiogenesis, and blockade of glucose transport pathways.

The p53 Pathway and Proteasome Inhibition

One of the more extensively characterized mechanisms of fenbendazole in cancer biology involves its interaction with the ubiquitin-proteasome pathway. A 2012 study by Dogra and Mukhopadhyay published in the Journal of Biological Chemistry demonstrated that fenbendazole inhibits proteasomal enzymatic activity — specifically chymotrypsin-like, post-glutamyl, and trypsin-like activities — leading to the accumulation of regulatory proteins including cyclins, p53, and IκBα.

This proteasomal inhibition has several downstream consequences. Accumulation of p53 activates its transcriptional targets, including the cyclin-dependent kinase inhibitor p21, which reinforces cell cycle arrest. Simultaneously, the study observed upregulation of endoplasmic reticulum (ER) stress genes — including GRP78, GADD153, ATF3, IRE1α, and NOXA — which contribute to apoptotic signaling. Notably, these effects were observed in cancer cells but not in normal cells tested under the same conditions.

A subsequent 2022 study by Park in Biological and Pharmaceutical Bulletin provided additional detail on cell cycle modulation: fenbendazole selectively suppressed growth in actively dividing cancer cells (but not quiescent cells), upregulated p21, and suppressed cyclin D1 and cyclin B1 expression — a profile consistent with dual G1/S and G2/M checkpoint engagement.

Glucose Metabolism Disruption

The Warburg effect — the preferential use of aerobic glycolysis by cancer cells — represents a metabolic vulnerability that several compounds target. Fenbendazole appears to interfere with this pathway through multiple mechanisms. The 2018 Dogra et al. study in Scientific Reports documented inhibition of GLUT transporter expression and blockade of hexokinase II (HKII), an enzyme critical for the first step of glycolysis in cancer cells.

A 2024 review by Nguyen et al. in Anticancer Research summarized these findings across multiple cancer types, including colorectal lineages: fenbendazole may inhibit glycolysis, downregulate glucose uptake, induce oxidative stress, and enhance apoptosis. The review also highlighted fenbendazole’s relatively high safety profile and low cost as practical advantages relevant to any potential translational development.

Animal Model Evidence

In vivo data provides a degree of translational context beyond cell culture findings. The 2018 Dogra et al. study demonstrated that orally administered fenbendazole blocked tumor growth in xenograft models using nude mice. The oral route of administration is notable, as it mirrors the pharmacokinetic scenario most relevant to human use and confirms sufficient bioavailability to produce measurable antitumor effects in living organisms.

A 2024 review in Anticancer Research (Nguyen et al.) provided further discussion of oral fenbendazole pharmacokinetics, noting its high safety profile and low cost as practical advantages. However, the authors also emphasized that optimal human dosing has not been established and that clinical trials would be required to characterize efficacy and safety in human cancer patients.

Dose-Dependent Effects and Selectivity

Several studies indicate that fenbendazole’s cytotoxic effects in cancer cells appear to be dose-dependent. The 2022 Park study in Biological and Pharmaceutical Bulletin observed selective suppression of actively growing cancer cells but not quiescent cells — a finding consistent with the microtubule-targeting mechanism, which primarily affects dividing cell populations. This selectivity profile differentiates fenbendazole from some non-selective cytotoxic agents, though direct comparison with clinical chemotherapy agents would require well-controlled human trial data.

The Son et al. 2020 review in Immune Network confirmed that benzimidazoles including fenbendazole show activity against therapy-resistant cancer cells in addition to treatment-naïve lines, broadening the potential utility of this mechanism class in colorectal cancer research.

Summary

Laboratory research published between 2012 and 2024 indicates that fenbendazole may affect colorectal cancer cells through several interconnected mechanisms: microtubule destabilization leading to G2/M arrest, proteasome inhibition and p53 pathway activation, and disruption of glucose metabolism via GLUT transporter and HKII suppression. Studies have demonstrated cytotoxicity in CRC cell lines including drug-resistant variants, and oral administration has produced antitumor effects in animal models.

These findings represent a foundation for further investigation. The translation of preclinical data into clinical evidence requires rigorous human trials, which have not yet been conducted for fenbendazole in colorectal cancer. Until such data are available, the findings described here remain confined to the laboratory setting.